Actively Recruiting
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
Led by UNICANCER · Updated on 2025-12-02
400
Participants Needed
1
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types.
CONDITIONS
Official Title
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before any trial procedures
- Age 18 years or older
- Diagnosed with unresectable locally advanced or metastatic breast, urothelial, non-small cell lung, or gastric cancer eligible for ADC treatment
- At least two tumor lesions: one measurable by RECIST V1.1 and one accessible for biopsy excluding bone and brain
- Tumor site accessible for biopsy with agreement to pretreatment and post-treatment biopsies; archival biopsy allowed if recent and sufficient
- Life expectancy of at least 12 weeks
- ECOG performance status of 0 to 2
- Adequate blood and organ function suitable for ADC treatment
- Agreement to use contraception during trial and after treatment as specified
- Affiliated with social security or equivalent
- Willing and able to follow the trial protocol
- Consent to use tumor and blood samples for future biomarker research
You will not qualify if you...
- Prior treatment with ADC in a curative setting
- Refusal to consent to sample use
- Presence of another progressive disease with short-term life-threatening prognosis
- Receiving concurrent treatment for a different cancer or hematologic disorder
- Inadequate washout period before treatment start including recent brain radiation, chemotherapy, immune therapy, hormonal therapy, surgery, or extensive radiotherapy as specified
- Pregnant, breastfeeding, or planning pregnancy during or shortly after study
- Person deprived of liberty or under guardianship or protective custody
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gustave Roussy Cancer Center
Villejuif, France, 94805
Actively Recruiting
Research Team
M
Marjorie Mauduit
CONTACT
J
Jérôme Lemonnier
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here